Detecting and characterizing tumor cells is critical for understanding cancer biology
Tumor cells change and display tremendous heterogeneity
Current cell sorting methods use antibodies for detection, but are inadequate as antigens can change over time, between patients, and after treatment
Circulating tumor cells (CTCs) are important rare cells that are crucial for understanding cancer biology and have great diagnostic value and are difficult to reliably detect using antibody-based methods.
Drug companies can use LumaCyte's Radiance instrument to understand changes in cell phenotype in response to drug candidates in pre-clinical research and testing
The Radiance™ instrument can:
Label Free Detection of T Cell activation
Quantify response of tumor cells to drug candidates using label-free analysis
Identify, characterize, and sort cancerous cell phenotypes
Quantitatively measure the changes in the cell's cytoskeleton which is known to correlate with metastatic potential
Analysis of tumor cells and their response to drug candidates is an important part of the drug discovery process. Current state-of-the-art cell analysis and sorting instruments rely almost exclusively on antibody labeling of surface markers in both cell lines and primary cells. This approach is limited because these antibody markers can alter the cells being studied, resulting in poor drug candidate selections[2,3]. For primary cells, the markers can change or disappear over time during patient treatment and vary greatly from patient to patient[4-6]. Subtle changes in cells and populations can be detected using LumaCyte’s label-free technology resulting in better drug candidate assessment.